Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biogen Builds Out Neuroscience Niche With Ischemic Stroke Drug

Executive Summary

Biogen acquired rights to Remedy's Cirara, a Phase III-ready candidate in development for large hemispheric infarction, a severe stroke where brain swelling causes high mortality.

You may also be interested in...



A Deal For Biogen, But Not The One Investors Are Waiting For

The firm announced a small deal with Karyopharm for a preclinical asset with potential in ALS, but large deals are also being considered, management told the fourth quarter earnings call.

J.P. Morgan Notebook Day 1: Tax Reform At Last, Allergan's Job Cuts, Teva Turnaround, Biogen's Cash, And Getting FDA-Friendly

Daily round-up of news and notes from the 2018 J.P. Morgan Healthcare Conference in San Francisco: US corporate tax reform becomes a reality, Allergan's Saunders defends patent moves as a means of protecting jobs, clarity on generic prices from Teva, Biogen's money to burn, and making the most of FDA flexibility.

J.P. Morgan Notebook Day 1: Tax Reform At Last, Allergan's Job Cuts, Teva Turnaround, Biogen's Cash, And Getting FDA-Friendly

Daily round-up of news and notes from the 2018 J.P. Morgan Healthcare Conference in San Francisco: US corporate tax reform becomes a reality, Allergan's Saunders defends patent moves as a means of protecting jobs, clarity on generic prices from Teva, Biogen's money to burn, and making the most of FDA flexibility.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC098744

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel